Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €1.01 EUR
Change Today +0.066 / 7.02%
Volume 1.4M
TIG On Other Exchanges
EN Brussels
As of 11:35 AM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).

tigenix nv (TIG) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/1/15 - €1.31
52 Week Low
12/17/14 - €0.48
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TIGENIX NV (TIG)

Related News

No related news articles were found.

tigenix nv (TIG) Related Businessweek News

No Related Businessweek News Found

tigenix nv (TIG) Details

TiGenix NV, a biopharmaceutical company, develops and commercializes cell therapy products. Its pipeline is based on a validated platform of allogeneic expanded adipose-derived stem cells (eASC) targeting autoimmune and inflammatory diseases. The company is developing Cx601, which is in Phase III clinical trials for the treatment of complex perianal fistulas in patients suffering from Crohn’s disease; Cx611, an allogeneic eASC that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis and Phase Ib trail for severe sepsis; and Cx621, which has completed a Phase I trial for the treatment of intra lymphatic administration of allogeneic eASCs. It has operations in Belgium, the Netherlands, Spain, and internationally. TiGenix NV was founded in 2000 and is headquartered in Leuven, Belgium.

49 Employees
Last Reported Date: 03/27/15
Founded in 2000

tigenix nv (TIG) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: €476.6K
Compensation as of Fiscal Year 2014.

tigenix nv (TIG) Key Developments

TiGenix NV Completes Enrolment of Phase I/II Study in Acute Myocardial Infarction

TiGenix NV announced that it has completed enrolment of its Phase II study in acute myocardial Infarction (CAREMI study). CAREMI is a two phase study consisting of an open-label dose-escalation phase I completed in June 2015, and a randomised, double-blind, placebo-controlled phase II, aiming at evaluating the safety and efficacy of intracoronary infusion of AlloCSC-01, a suspension of allogeneic human cardiac stem cells (CSCs), in patients that have suffered an acute myocardial infarction (AMI). Enrolment of this second phase has been completed with the treatment of the last of the planned 49 patients. The trial has now entered in its 12 month follow-up period. The company believes AlloCSC-01 may become a new approach to prevent cardiac remodelling and the onset of Chronic Heart Failure (CHF) after AMI. In the United States and Europe, approximately 1.5 million AMIs are treated annually. Current AMI management therapeutic options including Percutaneous Transluminal Coronary Angioplasty (PTCA), combined with stent implantation, are in most cases successful in re-establishing the perfusion of the ischemic myocardium and have helped to reduce the immediate mortality after infarct. However, these treatments are not able to recover the injured tissue. In fact all currently approved therapeutic approaches are palliative and designed to preserve the function of the surviving myocardium. The CAREMI trial will help to establish AlloCSC-01 as a potential means to reduce the damage caused by the infarct and improve the prognosis of AMI patients in this very large indication. Eight clinical centers of reference in cardiology have participated in the CAREMI trial led by Prof. Fernández-Avilés of Hospital Gregorio Marañón in Madrid, Spain, and Prof. Stefan Janssens of KU Leuven, Belgium, as principal investigators. The CAREMI trial has been supported by the Seventh Framework Programme of the European Commission, a transnational research funding initiative, as part of the CARE-MI project (Grant Number 242038).

TiGenix N.V. Presents at ARM's 3rd Annual EU Advanced Therapies Investor Day 2015, Nov-12-2015

TiGenix N.V. Presents at ARM's 3rd Annual EU Advanced Therapies Investor Day 2015, Nov-12-2015. Venue: Royal Institute of British Architects, 66 Portland Place, London W1B 1AD, United Kingdom. Presentation Date & Speakers: Nov-12-2015, Eduardo Bravo Fernández de Araoz, Chief Executive Officer, Managing Director and Director.

TiGenix N.V. Presents at BIO-Europe 2015, Nov-02-2015

TiGenix N.V. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TIG:BB €1.01 EUR +0.066

TIG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Vericel Corp $2.24 USD +0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation TIG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.2x
Price/Book 6.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.7x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TIGENIX NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at